Fluphenazine decanoate (depot) and enanthate for schizophrenia

Maayan, Nicola; Quraishi, Seema; David, Anthony S.; Jayaswal, Aprajita; Eisenbruch, Maurice; Rathbone, John; Asher, Rosie; Adams, Clive E

doi:10.1002/14651858.cd000307.pub2

Cited by 13 publications

(8 citation statements)

References 209 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the level of statistical significance set at P = 0.05 (two-sided) and a study power of 80 %, the sample size was 47 per group to detect an average effect size (Cohen’s d) of 0.50 on the above two outcomes, using G*Power 3.1 for Windows [20], taking into account an attrition rate of 20 % [10,19]. Hence, 114 participants were randomly selected (n = 57 in each group).…”

Section: Methodsmentioning

confidence: 99%

“…Indeed, it also reflects the recognized needs for, and importance of taking the prescribed medication from the patient’s perspective [2,9,10]. Systematic reviews on recent clinical trials indicate that current multi-faceted and complex psychosocial interventions for people with schizophrenia can only demonstrate modest and inconsistent effects on improving patients’ treatment adherence and/or other psychosocial outcomes over a short-term follow-up period (for example, six months) [2,3,11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial

Chien

Mui

Cheung

et al. 2015

Trials

127

View full text Add to dashboard Cite

BackgroundNon-adherence to antipsychotic medication is commonly found in schizophrenia and other psychotic disorders, thus forming a major obstacle to long-term maintenance treatment and contributing to high relapse rates. With limited evidence on the success of interventions in enhancing medication adherence, this controlled trial was designed to test and evaluate the effectiveness of an adherence therapy (AT) for outpatients with schizophrenia spectrum disorders, based on a motivational interviewing approach over a six-month follow-up period.MethodsA single-blind, randomized controlled trial with a repeated-measures, two parallel groups design was conducted in a random sample of 114 participants with schizophrenia spectrum disorders in one community psychiatric nursing service. After pre-test, the participants were randomly assigned to either an eight-session course of AT plus usual care or usual psychiatric care (n = 57 per group). The main outcomes, including medication adherence, symptom severity, insight into treatment, hospitalization rate, and functioning, were measured at baseline and immediately and six months post-intervention.ResultsA total of 110 participants completed this trial and thus the attrition rate was 3.5 %. Results of repeated-measures analysis of variance followed by Helmert’s contrasts test indicated that the AT participants reported significantly greater improvements in their insight into illness and/or treatment, psychosocial functioning, symptom severity, number of re-hospitalizations, and medication adherence (F = 5.01 to 7.45, P = 0.007 to 0.030) over six months follow-up, when compared with usual care.ConclusionsMotivational interviewing-based AT for people with schizophrenia can be effective to reduce symptom severity and re-hospitalizations, and improve medication adherence, functioning, and insight into illness and/or treatment over a medium term (six months) period of follow-up. Further study on the effects of AT in people with psychotic disorders in terms of diverse sociodemographic and illness characteristics, and a longer term (for example, over 12 months) follow-up period is recommended.Trial registrationThe trial was registered at Clinicaltrials.gov (identifier: NCT01780116) on 6 July 2014.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial

Chien

Mui

Cheung

et al. 2015

Trials

127

View full text Add to dashboard Cite

show abstract

“…This medication is accessible in various forms, namely, oral tablets and short acting, decanoate(depot) and enantoate ampules 8 . The effect of fluphenazine decanoate lasts for about 4–6 weeks 9 . Anticholinergic and extrapyramidal symptoms, such as sedation, dizziness, obesity, constipation, dry mouth and eyes, blurry vision, and urinary retention, are also among the common adverse reactions of fluphenazine decanoate 9,10 .…”

Section: Introductionmentioning

confidence: 99%

“…The effect of fluphenazine decanoate lasts for about 4–6 weeks 9 . Anticholinergic and extrapyramidal symptoms, such as sedation, dizziness, obesity, constipation, dry mouth and eyes, blurry vision, and urinary retention, are also among the common adverse reactions of fluphenazine decanoate 9,10 . The reported cardiovascular adverse effects of fluphenazine decanoate are myocarditis, cardiomyopathy, orthostatic hypotension with low incidence risk and corrected QT prolongation, and TdP with medium incidence risk 8,11,12 …”

Section: Introductionmentioning

confidence: 99%

“…9 Anticholinergic and extrapyramidal symptoms, such as sedation, dizziness, obesity, constipation, dry mouth and eyes, blurry vision, and urinary retention, are also among the common adverse reactions of fluphenazine decanoate. 9,10 The reported cardiovascular adverse effects of fluphenazine decanoate are myocarditis, cardiomyopathy, orthostatic hypotension with low incidence risk and corrected QT prolongation, and TdP with medium incidence risk. 8,11,12 Since no case of fluphenazine decanoate-induced bradycardia has been so far documented; this report is about the patient who developed this complication.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Fluphenazine decanoate‐induced bradycardia: A case report

Kamali

Zarghami

Azizi

et al. 2022

Neuropsychopharm Rep

View full text Add to dashboard Cite

Antipsychotic agents are administered for the management of schizophrenia and schizoaffective disorders. 1 Long-acting injectable antipsychotics are usually prescribed for maintenance therapy in non-compliant/non-adherent psychotic patients. 2 The negative cardiovascular complications of antipsychotic agents include sinus tachycardia, orthostatic hypotension, polymorphic ventricular tachycardia (VT), for example, torsade de pointes or (TdP), myocarditis, cardiomyopathy, and myocardial infarction (MI). 3,4 A case report in this field had accordingly revealed bradycardia and prolonged QTc interval upon using ziprasidone in a 25-year-old man. 5 Another case had further reported sinus bradycardia, chest pain, and syncope after 1.5 mg/day risperidone administration. 6 Moreover, symptomatic bradycardia and hypotension had been simultaneously detected while taking quetiapine in a 72-year-old individual with a history of heart disease. 7 Fluphenazine decanoate, as a conventional or first-generation antipsychotic (FGA) agent, is a member of the phenothiazine-derived neuroleptics, which acts principally through the antagonism of

show abstract

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia

Sampford

Sampson

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Measures of clinical response and mental state do not highlight differences between fluphenazine and amisulpride, risperidone, quetiapine or olanzapine. Largely measures of adverse effects are also unconvincing for substantive differences between fluphenazine and the newer drugs. All included trials carry a substantial risk of bias regarding reporting of adverse effects and this bias would have favoured the newer drugs. The four small short included studies do not provide much clear information about the relative merits or disadvantages of oral fluphenazine compared with newer atypical antipsychotics.

show abstract

Fluphenazine decanoate (depot) and enanthate for schizophrenia

Cited by 13 publications

References 209 publications

Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial

Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial

Fluphenazine decanoate‐induced bradycardia: A case report

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia

Contact Info

Product

Resources

About